Biomarkers to improve functional outcome prediction after ischemic stroke: Results from the SICFAIL, STRAWINSKI, and PREDICT studies
European Stroke Journal · 2024
DOI: 10.1177/23969873241250272 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Stroke Journal, 2024. Verfasst von Felipe A Montellano und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität (JMU) Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Biomarkers, Ischemic Stroke, Atrial Natriuretic Factor, Glycopeptides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg, Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft.
Themen: Schlaganfall
Abstract (Originalsprache)
Background and aims: Acute ischemic stroke (AIS) outcome prognostication remains challenging despite available prognostic models. We investigated whether a biomarker panel improves the predictive performance of established prognostic scores.
Methods
We investigated the improvement in discrimination, calibration, and overall performance by adding five biomarkers (procalcitonin, copeptin, cortisol, mid-regional pro-atrial natriuretic peptide (MR-proANP), and N-terminal pro-B-type natriuretic peptide (NT-proBNP)) to the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) and age/NIHSS scores using data from two prospective cohort studies (SICFAIL, PREDICT) and one clinical trial (STRAWINSKI). Poor outcome was defined as mRS > 2 at 12 (SICFAIL, derivation dataset) or 3 months (PREDICT/STRAWINSKI, pooled external validation dataset).
Results
Among 412 SICFAIL participants (median age 70 years, quartiles 59–78; 63% male; median NIHSS score 3, quartiles 1–5), 29% had a poor outcome. Area under the curve of the ASTRAL and age/NIHSS were 0.76 (95% CI 0.71–0.81) and 0.77 (95% CI 0.73–0.82), respectively. Copeptin (0.79, 95% CI 0.74–0.84), NT-proBNP (0.80, 95% CI 0.76–0.84), and MR-proANP (0.79, 95% CI 0.75–0.84) significantly improved ASTRAL score’s discrimination, calibration, and overall performance. Copeptin improved age/NIHSS model’s discrimination, copeptin, MR-proANP, and NT-proBNP improved its calibration and overall performance. In the validation dataset (450 patients, median age 73 years, quartiles 66–81; 54% men; median NIHSS score 8, quartiles 3–14), copeptin was independently associated with various definitions of poor outcome and also mortality. Copeptin did not increase model’s discrimination but it did improve calibration and overall model performance.
Discussion
Copeptin, NT-proBNP, and MR-proANP improved modest but consistently the predictive performance of established prognostic scores in patients with mild AIS. Copeptin was most consistently associated with poor outcome in patients with moderate to severe AIS, although its added prognostic value was less obvious.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität (JMU) Würzburg, Würzburg, Germany.
- Department of Neurology, University Hospital Würzburg, Würzburg, Germany.
- Interdisciplinary Center for Clinical Research, University Hospital Würzburg, Würzburg, Germany.
- Institute of Medical Data Science, University Hospital Würzburg, Würzburg, Germany.
- Neurovascular Research Laboratory, Vall d'Hebron Institute of Research, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
ORCID-Profile: Felipe A Montellano, Benjamin Hotter, Joan Montaner
Förderung
- Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg
- Bundesministerium für Bildung und Forschung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Montellano, F. A., Rücker, V., Ungethüm, K., Penalba, A., Hotter, B., Giralt, M., Wiedmann, S., Mackenrodt, D., Morbach, C., Frantz, S., Störk, S., Whiteley, W. N., Kleinschnitz, C., Meisel, A., Montaner, J., Haeusler, K. G., & Heuschmann, P. U. (2024). Biomarkers to improve functional outcome prediction after ischemic stroke: Results from the SICFAIL, STRAWINSKI, and PREDICT studies. European Stroke Journal. https://doi.org/10.1177/23969873241250272
Vancouver
Montellano FA, Rücker V, Ungethüm K, Penalba A, Hotter B, Giralt M, et al. Biomarkers to improve functional outcome prediction after ischemic stroke: Results from the SICFAIL, STRAWINSKI, and PREDICT studies. European Stroke Journal. 2024. doi:10.1177/23969873241250272
BibTeX
@article{Montellano2024,
author = {Montellano, Felipe A and Rücker, Viktoria and Ungethüm, Kathrin and Penalba, Anna and Hotter, Benjamin and Giralt, Marina and Wiedmann, Silke and Mackenrodt, Daniel and Morbach, Caroline and Frantz, Stefan and Störk, Stefan and Whiteley, William N and Kleinschnitz, Christoph and Meisel, Andreas and Montaner, Joan and Haeusler, Karl Georg and Heuschmann, Peter U},
title = {Biomarkers to improve functional outcome prediction after ischemic stroke: Results from the SICFAIL, STRAWINSKI, and PREDICT studies},
journal = {European Stroke Journal},
year = {2024},
doi = {10.1177/23969873241250272}
}
EUVIMED